The 36-month beta value for CRDF is at 1.95. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CRDF is 42.78M, and currently, shorts hold a 16.14% of that float. The average trading volume for CRDF on September 12, 2024 was 549.50K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CRDF) stock’s latest price update
The stock of Cardiff Oncology Inc (NASDAQ: CRDF) has increased by 9.52 when compared to last closing price of 2.31.Despite this, the company has seen a gain of 14.48% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-12 that Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.
CRDF’s Market Performance
CRDF’s stock has risen by 14.48% in the past week, with a monthly rise of 12.44% and a quarterly drop of -14.24%. The volatility ratio for the week is 6.63% while the volatility levels for the last 30 days are 5.72% for Cardiff Oncology Inc The simple moving average for the last 20 days is 10.19% for CRDF’s stock, with a simple moving average of -8.03% for the last 200 days.
Analysts’ Opinion of CRDF
Many brokerage firms have already submitted their reports for CRDF stocks, with Craig Hallum repeating the rating for CRDF by listing it as a “Buy.” The predicted price for CRDF in the upcoming period, according to Craig Hallum is $8 based on the research report published on September 06, 2024 of the current year 2024.
Robert W. Baird gave a rating of “Outperform” to CRDF, setting the target price at $19 in the report published on December 08th of the previous year.
CRDF Trading at 10.00% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.59% of loss for the given period.
Volatility was left at 5.72%, however, over the last 30 days, the volatility rate increased by 6.63%, as shares surge +18.33% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +24.02% upper at present.
During the last 5 trading sessions, CRDF rose by +16.72%, which changed the moving average for the period of 200-days by +111.44% in comparison to the 20-day moving average, which settled at $2.32. In addition, Cardiff Oncology Inc saw 70.95% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from PACE GARY W, who purchase 30,000 shares at the price of $1.37 back on Dec 19 ’23. After this action, PACE GARY W now owns 697,761 shares of Cardiff Oncology Inc, valued at $41,100 using the latest closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -67.11 for the present operating margin
- 0.37 for the gross margin
The net margin for Cardiff Oncology Inc stands at -61.44. The total capital return value is set at -0.83. Equity return is now at value -58.80, with -49.98 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -17.4. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -53.84.
Currently, EBITDA for the company is -45.01 million with net debt to EBITDA at 0.54. When we switch over and look at the enterprise to sales, we see a ratio of 142.05. The receivables turnover for the company is 1.47for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.97.
Conclusion
In conclusion, Cardiff Oncology Inc (CRDF) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
